Carpenter K A, Schmidt R, von Mentzer B, Haglund U, Roberts E, Walpole C
Department of Chemistry, AstraZeneca R&D Montreal, 7171 Frédérick-Banting, Saint-Laurent, Québec, Canada H4S 1Z9.
Biochemistry. 2001 Jul 27;40(28):8317-25. doi: 10.1021/bi0102860.
The 37-amino acid calcitonin gene-related peptide (CGRP) is a potent endogenous vasodilator thought to be implicated in the genesis of migraine attack. CGRP antagonists may thus have therapeutic value for the treatment of migraine. The CGRP C-terminally derived peptide [D(31),P(34),F(35)]CGRP(27-37)-NH(2) was recently identified as a high-affinity hCGRP(1) receptor selective antagonist. Reasonable CGRP(1) affinity has also been demonstrated for several related analogues, including [D(31),A(34),F(35)]CGRP(27-37)-NH(2). In the study presented here, conformational and structural features in CGRP(27-37)-NH(2) analogues that are important for hCGRP(1) receptor binding were explored. Structure-activity studies carried out on [D(31),P(34),F(35)]CGRP(27-37)-NH(2) resulted in [D(31),P(34),F(35)]CGRP(30-37)-NH(2), the shortest reported CGRP C-terminal peptide analogue exhibiting reasonable hCGRP(1) receptor affinity (K(i) = 29.6 nM). Further removal of T(30) from the peptide's N-terminus greatly reduced receptor affinity from the nanomolar to micromolar range. Additional residues deemed critical for hCGRP(1) receptor binding were identified from an alanine scan of [A(34),F(35)]CGRP(28-37)-NH(2) and included V(32) and F(37). Replacement of the C-terminal amide in this same peptide with a carboxyl, furthermore, resulted in a greater than 50-fold reduction in hCGRP(1) affinity, thus suggesting a direct role for the amide moiety in receptor binding. The conformational properties of two classes of CGRP(27-37)-NH(2) peptides, [D(31),X(34),F(35)]CGRP(27-37)-NH(2) (X is A or P), were examined by NMR spectroscopy and molecular modeling. A beta-turn centered on P(29) was a notable feature consistently observed among active peptides in both series. This turn led to exposure of the critical T(30) residue to the surrounding environment. Peptides in the A(34) series were additionally characterized by a stable C-terminal helical turn that resulted in the three important residues (T(30), V(32), and F(37)) adopting consistent interspatial positions with respect to one another. Peptides in the P(34) series were comparatively more flexible at the C-terminus, although a large proportion of the [D(31),P(34),F(35)]CGRP(27-37)-NH(2) calculated conformers contained a gamma-turn centered on P(34). These results collectively suggest that turn structures at both the C-terminus and N-terminus of CGRP(27-37)-NH(2) analogues may help to appropriately orient critical residues (T(30), V(32), and F(37)) for hCGRP(1) receptor binding.
37个氨基酸的降钙素基因相关肽(CGRP)是一种强效内源性血管舒张剂,被认为与偏头痛发作的发生有关。因此,CGRP拮抗剂可能对偏头痛治疗具有治疗价值。CGRP C末端衍生肽[D(31),P(34),F(35)]CGRP(27 - 37)-NH₂最近被鉴定为一种高亲和力的人CGRP(1)受体选择性拮抗剂。对于几种相关类似物,包括[D(31),A(34),F(35)]CGRP(27 - 37)-NH₂,也已证明具有合理的CGRP(1)亲和力。在本文介绍的研究中,探索了CGRP(27 - 37)-NH₂类似物中对人CGRP(1)受体结合很重要的构象和结构特征。对[D(31),P(34),F(35)]CGRP(27 - 37)-NH₂进行的构效关系研究产生了[D(31),P(34),F(35)]CGRP(30 - 37)-NH₂,这是报道的最短的CGRP C末端肽类似物,表现出合理的人CGRP(1)受体亲和力(K(i)=29.6 nM)。从肽的N末端进一步去除T(30)大大降低了受体亲和力,从纳摩尔范围降至微摩尔范围。通过对[A(34),F(35)]CGRP(28 - 37)-NH₂的丙氨酸扫描鉴定出了其他被认为对人CGRP(1)受体结合至关重要的残基,包括V(32)和F(37)。此外,将该相同肽中的C末端酰胺替换为羧基,导致人CGRP(1)亲和力降低超过50倍,因此表明酰胺部分在受体结合中起直接作用。通过核磁共振光谱和分子建模研究了两类CGRP(27 - 37)-NH₂肽,即[D(31),X(34),F(35)]CGRP(27 - 37)-NH₂(X为A或P)的构象性质。以P(29)为中心的β-转角是在两个系列的活性肽中始终观察到的一个显著特征。这个转角导致关键残基T(30)暴露于周围环境。A(34)系列的肽还具有稳定的C末端螺旋转角特征,导致三个重要残基(T(30)、V(32)和F(37))彼此之间具有一致的空间位置。P(34)系列的肽在C末端相对更灵活,尽管[D(31),P(34),F(35)]CGRP(27 - 37)-NH₂计算出的构象中有很大一部分包含以P(34)为中心的γ-转角。这些结果共同表明,CGRP(27 - 37)-NH₂类似物C末端和N末端的转角结构可能有助于将关键残基(T(30)、V(32)和F(37))以适当的方向排列,以实现与人CGRP(1)受体的结合。